Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study

Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study

Hui Liu,1,2 Haiyan Cao,3 Ting Li,4 Xinlei Chen,1 Hongling Yu,1 Jingfang Sun,3 Yerong Yu1 1Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, Sichuan, People’s Republic of China; 2Clinical Trial Center, West China Hospital of Sichuan University, Chengdu, S...

Full description

Saved in:
Bibliographic Details
Main Authors: Liu H, Cao H, Li T, Chen X, Yu H, Sun J, Yu Y
Format: Article
Language:English
Published: Dove Medical Press 2025-04-01
Series:Drug Design, Development and Therapy
Subjects:
b01711
idegasp
euglycemic clamp study
pharmacokinetics
healthy subjects
Online Access:https://www.dovepress.com/evaluation-of-pharmacokinetics-and-safety-of-the-biosimilar-b01711-and-peer-reviewed-fulltext-article-DDDT
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/evaluation-of-pharmacokinetics-and-safety-of-the-biosimilar-b01711-and-peer-reviewed-fulltext-article-DDDT

Similar Items